BridgeMD
New treatment option for AML, Adult
Official title Pharmacoscopy-guided Clinical Standard-of-care in r/r AML
ClinicalTrials.gov ID: NCT06138990
What this study is testing
What is Clinical standard-of-care (physician's choice)?
Clinical standard-of-care (physician's choice) is an investigational medicine, being studied as a potential treatment for aml, adult.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- With an overall survival of below 12 months, the outcome of relapsed/refractory AML (RR AML) is poor, making it a critical challenge to identify effective therapies at this stage. The RAPID-01 trial aims to show for the first time in a randomized and controlled clinical trial that Pharmacoscopy (PCY), a functional precision medicine platform, helps improve clinical standard-of-care treatment selection for patients suffering from relapsed/refractory AML.
- Phase 2: a mid-size study of how well it works
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 70
You may be able to join if
- Patient with refractory or relapsed AML according to ELN2022 criteria.
- Age 18-70 years.
- Considered to be eligible for intensive chemotherapy.
- Written informed consent.
You likely can't join if
- Acute promyelocytic leukemia (APL) with PML-RARA or one of the other pathognomonic variant fusion genes/chromosome translocations.
- Blast crisis after chronic myeloid leukemia (CML).
- Considered not eligible for intensive chemotherapy.
- Condition of the patient does not allow to wait for PCY results (patient requires immediate treatment).
- PCY not working / patient sample did not pass the QC steps of PCY.
- Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the principal...
See the full eligibility criteria
- Patient with refractory or relapsed AML according to ELN2022 criteria.
- Age 18-70 years.
- Considered to be eligible for intensive chemotherapy.
- Written informed consent.
- Acute promyelocytic leukemia (APL) with PML-RARA or one of the other pathognomonic variant fusion genes/chromosome translocations.
- Blast crisis after chronic myeloid leukemia (CML).
- Considered not eligible for intensive chemotherapy.
- Condition of the patient does not allow to wait for PCY results (patient requires immediate treatment).
- PCY not working / patient sample did not pass the QC steps of PCY.
- Any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the principal investigator may interfere with the project or affect patient compliance.
- Legal incompetence or people lacking capacity to provide informed consent.
- Participation in a clinical trial with an investigational drug within the 30 days preceding and during the present investigation.
The study team makes the final eligibility decision.
Where it's taking place
- Bern, Canton of Bern, Switzerland
- Zurich, Canton of Zurich, Switzerland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 70 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bern, Canton of Bern, Switzerland; Zurich, Canton of Zurich, Switzerland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.